VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
BEDFORD, Mass., July 30 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that scientists reporting in the July 31 issue of SCIENCE have discovered a key disease-related biologic pathway using an integrated and ...
Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting
- THEROS CancerTYPE ID(R) predicts cancer origin with 75 percent accuracy in patients whose primary cancer was 'unknown' using traditional diagnostics -
SAN DIEGO, June 1 /PRNewswire/ -- bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular
TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
SAN DIEGO , May 18 /PRNewswire/ -- TriLink BioTechnologies, Inc. today announced that it has signed a service agreement with Osmetech Molecular
Diagnostics to supply reagents for Osmetech's recently launched eSensor(R) Cystic Fibrosis Carrier Detection (CFCD) System and the eSensor(R) XT-8 Syst...
Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays
MARSEILLE, France, May 4 /PRNewswire-FirstCall/ -- Ipsogen SA (Alternext
- FR0010626028 - ALIPS), a molecular
diagnostic company specialized in the
development, the manufacturing and the commercialization of diagnostic assays
for breast cancer and leukemia, today announces the signature of an ...
Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
Unique GeneXpert(R) System Capabilities Enable Powerful New TB Diagnostic Tool
SUNNYVALE, Calif., April 27 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD ) today announced the release of Xpert(R) MTB/RIF as a CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical...
Midwest Research Institute Launches Clinical Molecular Diagnostics Laboratory
Receives CLIA Certification and CAP Accreditation
PALM BAY, Fla., April 17 /PRNewswire-USNewswire/ -- To address the growing need for molecular
diagnostics, officials at the Florida Division of Midwest Research Institute (MRI) announced today that they have established a Clinical Molecular
Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
ANNAPOLIS, Md., March 31 /PRNewswire-FirstCall/ --PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new mechanism of action data for Valortim(R) were presented at the Keystone Symposia on Mol...
Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State
Test aiding diagnosis of mental retardation, birth defects, and autism spectrum and developmental disorders now approved for use on patients in New York
MADISON, N.J., March 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX ), the world's leading provider of diagnostic ...
Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed
CAMBRIDGE, Mass. and COLUMBUS, Ohio, Jan. 8 /PRNewswire/ --IntelligentMDx a developer and manufacturer of proprietary nucleic acid assays, today announced that verification studies of the IntelligentMDx BK Viral Quantitative Assay are complete.
Under the verification protocol the Limit of De...
Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
SAN DIEGO, Dec. 14 /PRNewswire/ -- bioTheranostics, a bioMerieux company
that discovers, develops and commercializes new molecular
diagnostic tests in
oncology, reported today findings from three studies using the company's
molecular breast cancer assay to predict risk of disease recurrence in
Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA
Fourth 'Moderate Complexity' Categorization Highlights GeneXpert(R) System Ease-of-Use
SUNNYVALE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq:
CPHD) today announced the U.S. Food & Drug Administration (FDA) categorized
Cepheid's Xpert(TM) MRSA/SA Blood ...
CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
VIENNA, Va., Oct. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation
(NYSE: CVM ) announced today that it has entered into a Material Transfer
Agreement (MTA) with the National Institutes of Health Clinical Center
(NIHCC) and the laboratory of Dr. Francesco M. Marincola, M.D., to
National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities
DENVER, Sept. 10 /PRNewswire-USNewswire/ -- National Jewish Health and
Roche Diagnostics Corporation have reached a strategic agreement to pursue
opportunities in the growing field of molecular
partnership will combine National Jewish's expertise in clinical testing
and care ...
Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network
BIRMINGHAM, Ala., Sept. 4 /PRNewswire/ -- Southern Research Institute
today announced that the National Institutes of Health (NIH) has selected
the organization to participate in the newly-funded Molecular
Probe Production Center Network (MLPCN). The MLPCN -- a collaborative
First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
Identifies deadly hospital pathogens A single, fast and accurate test identifies four Staph strains simultaneously
HUNTSVILLE, Ala., Aug. 4 /PRNewswire/ -- Diatherix Laboratories, an
independent clinical reference laboratory located in the Huds...
Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
SOMERSET, N.J., July 21 /PRNewswire-FirstCall/ -- Alfacell Corporation
(Nasdaq: ACEL ) today announced that a paper published in Molecular
Therapeutics (2008; 7(7):1871-9) reports that a combination of ONCONASE
(ranpirnase) and the thiazolidinedione antidiabetic drug rosiglitazone
BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections
BD GeneOhm(TM) Cdiff Assay Submitted for FDA Clearance
SAN DIEGO, July 7 /PRNewswire-FirstCall/ -- BD Diagnostics, a segment
of BD (Becton, Dickinson and Company) (NYSE: BDX ), announced today the CE
marking of the BD GeneOhm(TM) Cdiff molecular
assay for the rapid diagnosis
Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
Olympus Corporation to Support the Joint Program through the Provision of Novel Imaging Systems
Collaboration Will Bring Innovative Fluorescent Imaging Agent and System Technologies into Clinical Trials in Ovarian Cancer
PHILADELPHIA, TOKYO and WOBURN, Mass, J...
AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
-Specific biomarkers for molecular
tumor grade and endocrine benefit offer better prediction of individual patient outcome-
SAN DIEGO, May 13 /PRNewswire/ -- AviaraDx, Inc. today announced the
publication of an article describing the discovery, development and
validation of a new mol...
Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
STOCKHOLM, April 22 /PRNewswire/ --
- Summary: Using Protein Tomography(TM), Sidec Investigated in
Collaboration With Genmab the Molecular
Mode of Action of Humax- EGFr
(Zalutumumab). In This Study Sidec Showed That EGFr is Flexible and That
Zalutumumab Locks the EGFr Into a Very Compact Ina...
Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated
(Nasdaq: GPRO ) announced today that the Company has begun a pivotal U.S.
clinical trial of its investigational APTIMA(R) assay to detect human
papillomavirus (HPV), which causes cervical cancer.
"Starting this highly comp...
Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
The Next Step Involves Combining the 350+ Targeted Drugs on the Market and
in Clinical Development with Each Other to Block Key Pathways to Combat
Drug Resistance, Enhance Anticancer Effects, and Expand the Markets for Targeted Drugs
LAKE FOREST, Calif., Feb. 19 ...
QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues
Project to Utilize World-Class Software & Database Developed in West Michigan to Help Advance Disease Diagnosis and Treatment Options
VENLO, Netherlands and GRAND RAPIDS, Mich., Feb. 14 /PRNewswire/ -- The
Center for Molecular
Medicine (CMM) today announced the formation of a
Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
Contracts Give Access to Diagnostic Application of Research Technologies
FULLERTON, Calif., Jan. 22 /PRNewswire-FirstCall/ -- Beckman Coulter,
Inc. (NYSE: BEC ) announced today that it has signed four agreements with
National University of Ireland, Galway (NUI Galway) to direct assay
Study of Pathwork Diagnostics' Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
SUNNYVALE, Calif., Dec. 14 /PRNewswire/ -- Pathwork Diagnostics, a
genomics-based diagnostics company focused on oncology, announced that its
Pathwork(R) Tissue of Origin Test is the focus of a study published in the
January issue of The Journal of Molecular
Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
BOULDER, Colo., Oct. 23 /PRNewswire-FirstCall/ -- Tapestry
Pharmaceuticals, Inc. (Nasdaq: TPPH ), is presenting data today at the AACR-
NCI-EORTC International Conference on Molecular
Targets and Cancer
Therapeutics. This year's conference is being held October 22-26, 2007 at
the Moscone Conv...
Abbott's m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
Abbott Innovations Honored for Third Time in Five Years
ABBOTT PARK, Ill., Oct. 22 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT )
has received a 2007 Chicago Innovation Award for its m2000(TM) molecular
Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- RDEA119: A Potent and Selective MEK inhibitor with Favorable In Vitro and In Vivo Anti-Tumor Properties -
CARLSBAD, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Ardea Biosciences,
Inc. (Pink Sheets: ARDC), a company focused on the discovery and
development of small-molecule ther...
BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
Test to Simultaneously Identify Staphylococcus Aureus and Methicillin-Resistant Staphylococcus Aureus from Nasal Specimens
SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- BD Diagnostics, a segment
of BD (Becton, Dickinson and Company) (NYSE: BDX ), announced today that it
Avid Announces Results of AV-1 Molecular Imaging Agent for
Alzheimer's Disease Presented at AD/PD Meeting
PHILADELPHIA--(BUSINESS WIRE)--Mar 19, 2007 - Avid
Radiopharmaceuticals, Inc. (Avid), a product-focused molecular
imaging company, today announced the presentation of the first
results from a clinical study of 18F-AV-1/ZK (AV-1), a novel
radiopharmaceutical for positron emission tomography (PET) im...
DNA Therapeutics Reports a Novel Mechanism of Action and a
Biomarker of its Lead Molecule Dbait That Open an Innovative
Pathway-Targeting in Molecular Cancer Therapy
EVRY, France, April 12, 2007 /PRNewswire/ -- DNA Therapeutics
S.A. an emerging pharmaceutical company specialized in innovative
cancer therapy announces today the elucidation of a new mechanism
of action and the identification of a biomarker of its
first-in-class antitumoral lead molecule Dbait. I...
Amsterdam Molecular Therapeutics BV to present preclinical
proof-of-concept data on its gene therapy AMT-020 to treat acute
The research, done in collaboration with the Centro de
Investigación Médica Aplicada (CIMA) at the
University of Navarra, Pamplona, Spain, is being presented at
Porphyrins and Porphyrias Congress, Rotterdam, the Netherlands.
AMSTERDAM, the Netherlands, May 1st 2007 - Amsterdam Mole...
Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data
on Molecular Imaging Pharmaceutical for Prostate Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 4, 2007 - Researchers at
Molecular Insight Pharmaceuticals today announced the presentation
of preclinical data on MIP-1072, a radiolabeled, small molecule
molecular imaging pharmaceutical in development for diagnosis and
staging of prostate cancer at the 54th...
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
...ma and GAAP measures, which is explained later in this release.
As a result of selling Isis' diagnostic subsidiary, Ibis Biosciences, to Abbott molecular
Inc. (AMI) in the first quarter of 2009, Isis is reporting Ibis' financial results as discontinued operations. Accordingly, Isis has presented all pe...
DNA Helps Reunite Children With Their Families
...even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular
diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs...
ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer
...y. With more than 2,600 employees, ARUP offers in excess of 2,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular
and genetic assays, for patients nationwide. Rather than competing with its clients for physician office business, ARUP chooses instead to support cli...
CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical Research
...arch project into prostate cancer, the Dutch CTMM (Center
for Translational molecular
Medicine) today announced the successful
completion of 265 million euro fun...e Dutch
CTMM (Center for Translational molecular
Medicine) is a Netherlands-based
public-private partnership dedicated to th...
Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
... has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular
design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of...
Correction to Earlier Release From Jewish Hospital and University of Louisville
...ng the press conference Roberto Bolli, Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and Director of UofL's Institute for molecular
Cardiology, stated, "Another clinical trial is being conducted at another facility. The difference between what we have done and what another institu...
World's First Cardiac Adult Stem Cell Patient Receives Infusion
Study leader Roberto Bolli, Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and Director of UofL's Institute for molecular
Cardiology said, "We continue to enroll patients in this first-of-its-kind clinical trial. We hope to help the heart regenerate its own tissue and imp...